LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Option Care Health to Participate in Upcoming Investor Conferences

May 18, 2023 | Last Trade: US$22.81 0.11 -0.48

BANNOCKBURN, Ill., May 18, 2023 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • William Blair’s 43rd Annual Growth Stock Conference, being held in Chicago, on Tuesday, June 6, 2023, including a fireside chat at 11:30am CT.
  • The Jefferies Healthcare Conference, being held in New York City, on Wednesday, June 7, 2023, including a fireside chat at 12:30pm ET.
  • The 44th Annual Goldman Sachs Healthcare Conference, being held in Dana Point, CA, on Monday, June 12, 2023, including a fireside chat at 3:20pm PT.

Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

For Investor Inquiries:

Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB